Study design and methodologies for the men moving forward lifestyle intervention trial with black prostate cancer survivors.

Black/African-American men experience significantly higher prostate cancer incidence and mortality rates compared to men of other race/ethnicities.

• Comorbidities and compromised quality of life are described as greater challenges for Black men with prostate cancer.
• Body composition and health behaviors are identified as important yet modifiable contributors to these disparities.
• The paper characterizes Black men with prostate cancer as a 'high-risk, underrepresented population.'

Existing lifestyle interventions for prostate cancer survivors have critically limited inclusion of Black men.

• The paper states that 'the inclusion of Black men is critically limited' in lifestyle intervention research for PC survivors.
• This gap in the literature is identified as a primary motivation for the MMF trial.
• The MMF trial is described as addressing 'an important gap in the current literature.'

The Men Moving Forward (MMF) trial is designed to randomize 200 Black men with prostate cancer in a 1:1 ratio to intervention or wait-list control.

• Eligible participants are Black men with prostate cancer who have completed treatment or are on active surveillance.
• Randomization is 1:1 between the MMF intervention group and a wait-list control group.
• The target enrollment is 200 participants.
• The trial is registered with U.S. ClinicalTrials.gov number NCT03971591, registered 06.01.2019.

The 16-week MMF intervention is community-based, conducted in partnership with the Milwaukee Recreation system, and supports adoption of the American Cancer Society Nutrition and Physical Activity guidelines.

• The intervention duration is 16 weeks.
• The program was developed in partnership with the Milwaukee Recreation system.
• The intervention supports adoption of the American Cancer Society Nutrition and Physical Activity guidelines.
• The program is described as developed 'with and for Black men with PC.'

The primary hypothesis is that men receiving the MMF intervention will exhibit greater changes in body composition than those in the wait-list control group.

• Body composition is specified as the primary outcome measure.
• Secondary measures include behavior (diet, physical activity), fitness, quality of life, and biomarkers of general health and PC recurrence risk.
• Data are collected at three time points: baseline, post-intervention (16 weeks), and 12-month follow-up.

The MMF trial includes biomarkers of both general health and prostate cancer recurrence risk as outcome measures.

• Biomarkers of general health and PC recurrence risk are collected alongside behavioral and body composition outcomes.
• The paper states these outcomes 'add to our knowledge and methodologies on health behaviors and PC survivorship.'
• Study results are intended to 'inform survivorship efforts for this high-risk, underrepresented population.'